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We reported previously that the obesity hormone leptin
is overexpressed in breast cancer biopsies. Here, we investi-
gated molecular mechanisms involved in this process,
focusing on conditions that are associated with obesity,
that is, hyperinsulinemia and induction of hypoxia. By
using quantitative real-time PCR, immunoﬂuorescent
detection of proteins and enzyme-linked immunosorbent
assays, we found that treatment of MCF-7 breast cancer
cells with high doses of insulin or the hypoxia-mimetic
agent CoCl2, or culturing the cells under hypoxic
conditions signiﬁcantly increased the expression of leptin
mRNA and protein. Notably, the greatest leptin mRNA
and protein expression were observed under combined
hyperinsulinemia and hypoxia or hypoxia-mimetic treat-
ments. Luciferase reporter assays suggested that
increased leptin synthesis could be related to the activation
of the leptin gene promoter. DNA afﬁnity precipitation
and chromatin immunoprecipitation experiments revealed
that insulin, CoCl2 and/or hypoxia treatments augmented
nuclear accumulation of hypoxia-inducible factor-1a
(HIF-1a) and increased its interaction with several
upstream leptin regulatory sequences, especially with the
proximal promoter containing four hypoxia-response
elements and three GC-rich regions. By using reverse
chromatin precipitation, we determined that loading of
HIF-1a on the proximal leptin promoter concurred with
the recruitment of p300, the major HIF coactivator,
suggesting that the HIF/p300 complex is involved in leptin
transcription. The importance of HIF-1a in insulin- and
CoCl2-activated leptin mRNA and protein expression was
conﬁrmed using RNA interference.
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Introduction
Excess body weight has been shown to (by 30–50%)
increase signiﬁcantly postmenopausal breast cancer risk
(Klein et al., 2002; Calle and Thun, 2004). A very recent
report suggested that compared with non-obese breast
cancer patients, obese subjects more frequently pre-
sented with advanced disease characterized by large,
high grade, metastasizing tumors (Porter et al., 2006).
Although the molecular mechanism of obesity-related
mammary carcinogenesis is not clear, signiﬁcant role has
been suggested for cytokines produced by adipose tissue,
for example, leptin.
Leptin is a pleiotropic hormone whose major function
is to regulate food intake and energy balance by
interacting with satiety centers in the brain (Wauters
et al., 2000). Leptin also affects many peripheral organs,
behaving as a mitogen, survival factor, metabolic
regulator or angiogenic factor (Wauters et al., 2000).
Additionally, leptin appears to promote neoplastic
processes, including breast carcinogenesis (Garofalo
and Surmacz, 2006; Surmacz, 2007). In breast cancer
cellular models, leptin has been shown to stimulate cell
growth, survival and transformation and interfere with
the action of antiestrogens (Garofalo and Surmacz,
2006). In addition, leptin can modulate major pathways
involved in breast cancer progression. For instance,
binding of leptin to its receptor (ObR) has been shown
to transactivate the Her2/neu oncogenic receptor
(Eisenberg et al., 2004). Furthermore, leptin is able to
induce the expression of vascular endothelial growth
factor (VEGF) and its receptor VEGFR2 in mammary
tumors (Gonzalez et al., 2006). In agreement with this
ﬁnding, ObR peptide antagonists can inhibit mammary
tumor growth (Gonzalez et al., 2006).
Recently, others and we demonstrated that both
leptin and ObR can be found in breast cancer biopsies,
which suggests that leptin might affect breast cancer
cells through autocrine and/or paracrine mechanisms.
Importantly, the leptin system is overexpressed in breast
cancer tissues, especially in high grade (G3) tumors,
while it is absent or expressed at very low levels in
normal mammary epithelium or benign tumors (Ishika-
wa et al., 2004; Garofalo et al., 2006). We also
demonstrated that overexpression of leptin and ObR
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mRNA in breast cancer could be induced by obesity-
related stimuli, such as high concentrations of insulin or
estrogen (Garofalo et al., 2006). Overexpression of
leptin and ObR on the protein and mRNA levels in
breast cancer vs normal epithelium has been conﬁrmed
by other investigators (Ishikawa et al., 2004; Revillion
et al., 2006).
The mechanism of leptin induction in breast cancer
cells is unknown. Consequently, we investigated whether
insulin and hypoxia-mimetic agents might regulate the
expression of the leptin gene in this cell context. The
human leptin gene promoter isB3000 long and contains
several regulatory motifs, including AP2, SP-1, CREB,
C/EBP, GRE, CRE elements (Mason et al., 1998;
Ahima and Flier, 2000; Melzner et al., 2002; Meissner
et al., 2003). Most importantly, the promoter contains
eight hypoxia-responsive elements (HRE) with the
minimal core sequence 50-RCGTG-30 that can recruit
hypoxia-inducible factor (HIF) (Grosfeld et al., 2002;
Meissner et al., 2003). HIF is a master transcriptional
factor in nutrient stress signaling and can induce an
array of genes involved in energy metabolism, neovas-
cularization, survival, cell migration and pH balance. In
addition, HIF can promote metastatic processes by
activating tumor neoangiogenesis, and increasing cell
motility and invasion (Zhong et al., 1999; Hirota and
Semenza, 2006; Pouyssegur et al., 2006).
HIF is a heterodimer of a constitutively expressed HIF-
1b subunit and an oxygen-regulated, unstable HIF-1a
subunit. HIF activation involves HIF-1a stabilization, its
nuclear translocation, heterodimerization and interaction
with other transcriptional regulators, of which the most
important is p300, a histone acetyl transfersase (Ebert and
Bunn, 1998; Gray et al., 2005). HIF-1a expression is
signiﬁcantly increased under hypoxic conditions, but it
can also occur in normoxia upon activation of the mTOR
pathway (Pouyssegur et al., 2006). We investigated
whether in breast cancer cells, insulin, a potent inducer
of mTOR pathway and hypoxia-mimetic agents can
stimulate leptin expression through HIF-1a.
Results
Insulin, CoCl2 and hypoxia enhance nuclear accumulation
of HIF-1a in MCF-7 breast cancer cells
Previously, we reported that leptin is overexpressed in
breast cancer and that this overexpression might be
caused by obesity-related stimuli, such as hyperinsuli-
nemia or hypoxia-mimetic agents (Garofalo et al., 2006).
Because the leptin promoter contains multiple sites that
can recruit HIF, we hypothesized that increased leptin
expression might be related to accumulation of nuclear
HIF-1a, resulting in increased HIF loading on leptin
regulatory sequences. Thus, we assessed if insulin alone
or in combination with either hypoxia-mimetic agent
CoCl2 or physiological hypoxia could enhance nuclear
HIF-1a expression in MCF-7 cells (Figure 1).
The levels of nuclear HIF-1a were signiﬁcantly
increased by insulin in a dose-dependent manner, with
the maximum effects (B2.5-fold increase over control)
produced by the 340 nM dose (Figure 1a). CoCl2 and
hypoxia treatments stimulated nuclear HIF-1a accumu-
lation by B7- and B10-fold, respectively. The addition
of insulin at 85–680 nM doses did not enhance the effects
of CoCl2 or hypoxia (Figure 1b and data not shown).
Insulin, CoCl2 and hypoxia stimulate leptin mRNA
expression
Next, we used quantitative real-time–PCR (QRT–PCR)
to measure leptin mRNA expression under different
treatments in MCF-7 cells (Figure 2). Relative to basal
levels, addition of CoCl2 increased leptin mRNA by
Figure 1 Insulin, CoCl2 and hypoxia increase nuclear hypoxia-
inducible factor (HIF)-1a levels. HIF-1a expression was studied by
WB, as described in ‘Materials and methods’. (a) HIF-1a
expression in 100mg of nuclear proteins obtained from cells treated
for 4 h with 0–680 nM doses of insulin (Ins); (b) HIF-1a expression
in 50 mg of nuclear proteins obtained from cells untreated (C), or
treated for 4 h with 340 nM insulin (Ins), and/or CoCl2 and/or
hypoxia (Hyp). (a and b) Protein loading and purity of fractions
were controlled by re-probing WB ﬁlters for the expression of a
cytoplasmic protein b-tubulin (TUB) and a nuclear marker
nucleolin (NUC). Relative HIF-1a expression normalized to
NUC is presented in graphs; bars represent s.e.
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B1.8. Culturing the cells under hypoxia for 4 and 16 h
stimulated leptin mRNA by B2.1- and B3.9-fold,
respectively. Insulin alone was most effective in increas-
ing leptin mRNA at 340 and 680 nM doses. Remarkably,
the highest (over sixfold) leptin mRNA expression was
observed under combined insulin plus CoCl2 or insulin
plus hypoxia conditions (Figure 2).
Insulin, CoCl2 and hypoxia induce leptin protein
expression
The expression of intracellular leptin protein was
studied using immunoﬂuorescence and deconvoluted
microscopy, while the abundance of secreted leptin was
measured by enzyme-linked immunosorbent assay
(ELISA; Figure 3). Cellular leptin staining was detect-
able in 1571% of cells treated with 340 nM insulin,
55710% of cells under CoCl2 treatment and 6774% of
cells under hypoxia. The combined insulin plus CoCl2 or
hypoxia treatments resulted in 5576 and 6170% cells
positive for leptin staining, respectively (Figure 3).
Parallel experiments revealed low HIF-1a expression in
4074% of cells stimulated with insulin, and abundant
HIF-1a levels in 6274 and 8077% of cells treated with
CoCl2 and combined treatment, respectively (Figure 3).
Under hypoxia and hypoxia plus insulin, high HIF-1a
levels were detected in 8075 and 7877%, respectively
(Figure 3).
Next, we tested the effects of various treatments
on bioactive leptin secretion. Insulin alone was most
effective at 340 nM dose, stimulating synthesis of
16.270.2 pg/ml leptin, while insulin treatment at 170 nM
induced 14.271.0 pg/ml leptin and 680 and 1000 nM
induced 12.070.5 and 5.070.1 pg/ml leptin, respectively.
The greatest leptin synthesis was seen under combined
stimuli (340 nM insulin plus CoCl2 or plus hypoxia)
(Figure 3).
Leptin promoter is activated by insulin and hypoxia-
mimetic treatment in breast cancer cells
To address the molecular mechanism by which insulin
or hypoxia might activate leptin expression, we used the
reporter plasmid, pGL3-OB1, containing the luciferase
gene under the control of leptin regulatory sequences
(2924 to þ 31). Insulin and CoCl2 as well as the
combination of both stimuli signiﬁcantly induced
luciferase activity in MCF-7 cells transfected with
pGL3-OB1 relative to cells transfected with an empty
vector pGL3 (Figure 4). Speciﬁcally, insulin alone
increased luciferase activity by 40%, CoCl2 by 69%
and the combination of both by 111%.
Figure 2 Insulin, CoCl2 and hypoxia increase leptin mRNA
expression. The abundance of leptin mRNA was studied with
QRT–PCR in MCF-7 cells untreated (C) or treated for 4 h with
different doses of insulin (Ins), and/or 100mM CoCl2 and/or
hypoxia (Hyp), as described in ‘Materials and methods’. The graph
represents the increase of leptin mRNA relative to the increase of
a-actin mRNA in the same sample 7s.e.
Figure 3 Insulin, CoCl2 and hypoxia increase hypoxia-inducible factor (HIF)-1a and leptin protein expression. MCF-7 cells were
treated for 16 h with 340 nM insulin (Ins), and/or CoCl2 and/or hypoxia (Hyp), as described in ‘Materials and methods’. The expression
of HIF-1a (red ﬂuorescence) and leptin (LEP, green ﬂuorescence) was assessed by immunostaining with speciﬁc antibodies (Abs) and
deconvoluted microscopy, as detailed in ‘Materials and methods’. Cell nuclei were identiﬁed with DAPI (blue ﬂuorescence). In control
experiments (Abs C), primary Abs were omitted. In parallel, the abundance of secreted leptin (pg/ml) in conditioned medium of
untreated and treated cells was determined by ELISA, as described in ‘Materials and methods’.
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HIF-1a binds multiple HRE motifs in the leptin promoter
in vitro
To address molecular mechanisms of leptin promoter
activation in breast cancer cells, we assessed whether
increased nuclear accumulation of HIF-1a correlates
with elevated HIF-1a binding to HRE motifs. We
selected three HRE-containing regions (HRE-1, prox-
imal to ATG, HRE-2, in the middle of the leptin
promoter and HRE-3, most distant from ATG). By
using DNA afﬁnity precipitation assay (DAPA), we
found that CoCl2 and the combined CoCl2 plus insulin
treatment increased HIF-1a binding to all three HREs
(Figure 5). The greatest HIF-1a binding was seen with
HRE-1 and HRE-2, and the least with HRE-3. Insulin
stimulated signiﬁcant HIF-1a interaction with HRE-1,
but not with HRE-2 or HRE-3. Combined insulin plus
CoCl2 treatments produced results statistically similar to
that obtained with CoCl2 alone (Figure 5).
CoCl2 and insulin stimulate association of the HIF-1a/
p300 complex with the leptin promoter in vivo
Next, we tested using chromatin immunoprecipitation
(ChIP) assays if CoCl2 and insulin stimulate HIF-1a inter-
action with the leptin promoter in vivo. All treatments
signiﬁcantly increased HIF-1a binding to the proximal
leptin promoter region HRE-A. This region contains
four HRE sites, including described above HRE-1 and
HRE-2 as well as multiple GC-rich sequences that have
been shown to improve HIF activity (Miki et al., 2004)
(Figure 6). The greatest HIF-1a binding to HRE-A was
detected under insulin plus CoCl2 treatments, while the
lowest under insulin alone. By using reverse ChIP (re-
ChIP), we demonstrated that in all cases, the HIF-1
complex interacting with HRE-A contained the major
HIF coactivator p300 (Figure 6).
The HIF-1a/p300 complex was also detected on the
distal HRE-B region that contains two HRE sites, but in
this case the amounts of HIF-1a under all treatments
were signiﬁcantly lower than that seen with HRE-A.
Furthermore, no synergistic effects of CoCl2 and insulin
were noted (Figure 6). Neither HIF-1a nor p300 was
detected on the GAPDH promoter (which does not
contain HREs) under treatments used (data not shown).
CoCl2- and insulin-induced expression of leptin in breast
cancer cells requires HIF-1a
The requirement for HIF-1a in the activation of leptin
expression in breast cancer cells was studied using RNA
interference. We found thatB90% HIF-1a knockdown
was paralleled by B70% inhibition of leptin mRNA
synthesis (data not shown) and similar inhibition of
cellular leptin expression under all treatment conditions
(Figure 7).
Figure 4 Insulin and CoCl2 stimulate leptin promoter activity in
breast cancer cells. Leptin promoter activation was tested using
luciferase assays, as described in ‘Materials and methods’. The cells
transfected with the control plasmid (pGL3) or the leptin
promoter-luciferase plasmid (OB1) were treated with 340 nM
insulin (Ins), 100mM CoCl2 or left untreated (C). Luciferase
activity was calculated as relative fold induction vs untreated cells.
Bars represent s.e., asterisks (*) indicate statistically signiﬁcant
differences between pGL3 and OB1 transfections.
Figure 5 Hypoxia-inducible factor (HIF)-1a binds several hypoxia-responsive elements (HRE) motifs in the leptin promoter. The
binding of HIF-1a to three different leptin promoter regions was assessed in vitro by DAPA, as described in ‘Materials and methods’.
Each studied region contains one HIF motif, speciﬁcally, (120) ACGTC in HRE-1; (627) GCGTG in HRE-2 and (1501) ACGTG
in HRE-3. In control experiments (C), HIF-1a-HRE interactions were tested in the presence of excess unlabeled probes. The graphs
represent HIF abundance on HREs under different conditions 7s.e.
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Discussion
Although recent evidence suggests that the leptin/ObR
system is signiﬁcantly overexpressed in breast cancers and
related to tumor progression (Ishikawa et al., 2004;
Garofalo et al., 2006; Revillion et al., 2006; Snoussi et al.,
2006), molecular mechanisms underlying this phenomen-
on have not been delineated. Here, we demonstrated that
leptin expression in breast cancer cells can be induced by
hyperinsulinemia, hypoxia and/or hypoxia-mimetic treat-
ments, the conditions that can be associated with obesity
(Losso and Bawadi, 2005; Garofalo et al., 2006).
Figure 6 Hypoxia-inducible factor (HIF)-1a and p300 are corecruited to hypoxia-responsive elements (HRE)-containing regions in
the leptin promoter. The binding of HIF-1a and corecruitment of p300 to different leptin promoter regions was tested by chromatin
immunoprecipitation (ChIP) and reverse ChIP (re-ChIP) assays, as described in ‘Materials and methods’. The HRE-A region
encompasses four potential HRE binding sites, including those present in HRE1 and HRE2; the HRE-B region contains two potential
HIF binding sites, including that present in HRE3. DNA input in PCR reactions was assessed using HRE-A (not shown) and HRE-B
primers on samples before IPs. The graph represents relative abundance of HIF-1a or p300 on HREs under different conditions7s.e.
Figure 7 Hypoxia-inducible factor (HIF)-1a knockdown reduces leptin expression. (a) MCF-7 cells were transfected with HIF-1a
siRNA, as described in ‘Materials and methods’, or were left untransfected. In control experiments, the cells were transfected with
lamin A/C siRNA. The expression of HIF-1a was assessed by WB in whole cell protein lysates. The expression of b-tubulin (TUB) was
probed as control of protein loading. (b) The expression of HIF-1a and leptin (LEP) in MCF-7 cells transfected with HIF-1a siRNA
was studied by immunoﬂuorescence and deconvoluted microscopy as described in Figure 3 legend.
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First, we noted that the above treatments alone or in
combination increased nuclear expression of HIF-1a,
the HIF subunit that is known to be stabilized by
hypoxic conditions as well as by activation of the
insulin-sensitive mTOR pathway (Majumder et al.,
2004; Treins et al., 2005; Pore et al., 2006). In MCF-7
cells, nuclear accumulation of HIF-1a in response to
insulin was dose-dependent and maximal with the
340 nM dose. The greatest nuclear HIF-1a levels under
physiological hypoxia were seen at 16 h, and under
100 nM CoCl2 treatment at 4 h (Figure 1). Similar
conditions stimulated maximal leptin mRNA and leptin
protein expression. Notably, the highest leptin mRNA
and protein expression were observed under combined
insulin and hypoxia or CoCl2 treatments (Figures 2 and
3). The same conditions and with similar dynamics
appeared to stimulate the leptin gene promoter (from
2924 to þ 31; Figure 4). Although the same promoter
has previously been shown to respond to glucocorticoids
in 3T3-L1 cells (De Vos et al., 1998), and to insulin and
hypoxia in BeWo cells (Grosfeld et al., 2002; Meissner
et al., 2003), its activity in breast cancer cells has never
been described.
Because the leptin promoter contains multiple HRE
motifs, we tested whether high levels of insulin and
hypoxic conditions can stimulate leptin expression
through HIF. We demonstrated that in MCF-7 cells
nuclear HIF-1a is able to associate with several leptin
promoter domains containing HREs (Figures 5 and 6).
The highest HIF-1a binding was detected on the
proximal promoter (HRE-A), which contains four
HRE motifs as well as three GC-rich regions that can
enhance HIF activity (Miki et al., 2004). We also found
that the HIF-1a complex interacting with the proximal
promoter included p300 histone acetyltransferase, the
major HIF coactivator (Figure 6). In ChIP assays, we
noted that combined insulin plus CoCl2 treatment induced
slightly better HIF-1a loading on the proximal HRE-A
promoter region, compared with single treatments (Fig-
ure 6). These synergistic effects were not detected using
DAPA, possibly because this technique probes for protein
binding to short DNA fragments and cannot fully reﬂect
association of HIF-1a to native chromatin.
The above results are in agreement with data obtained
in chorioncarcinoma cell model, where increased leptin
expression was observed upon 500 nM insulin, hypoxia
and combined treatments (Meissner et al., 2003).
However, we are the ﬁrst to show that both stimuli
induce leptin in breast cancer cells acting through a
common pathway involving HIF-1a. Most studies on
leptin promoter activation relied on luciferase and other
in vitro assays. Our report is ﬁrst to demonstrate in vivo
that the HIF-1a/p300 complex interacts with and
activates the proximal leptin promoter in breast cancer
cells. Furthermore, we established that HIF-1a is not
only involved, but also required for insulin- and CoCl2-
stimulated leptin expression in MCF-7 cells.
Even though HIF seems to be a major factor
regulating leptin mRNA and protein expression in our
cell model, we acknowledge that it cannot be the
exclusive mediator of leptin expression. This is suggested
by the fact that addition of insulin to hypoxia or CoCl2
increased leptin mRNA and protein synthesis relative to
single treatments but did not elevate nuclear HIF-1a
levels and did not increase HIF-1a loading on distant
HREs (Figures 1b, 6 and 7). Furthermore, reduction of
HIF-1a expression by 90% was not sufﬁcient to produce
similar inhibition of leptin expression under combined
treatments (Figure 7). This suggest that leptin must be
regulated by other insulin-sensitive transcriptional
mechanism, as suggested before (Meissner et al., 2003).
In fact, we found that in some breast cancer cells, insulin
upregulates leptin expression predominantly via SP-1-
dependent mechanisms (data not shown).
Cumulatively, our results indicate that one of the
mechanisms of leptin overexpression in breast tumors
might involve HIF-1a, a component of HIF transcrip-
tional factor that can be upregulated by hypoxia and
hyperinsulinemia. Notably, HIF-1a is often overex-
pressed in invasive breast cancer (Vleugel et al., 2005)
and is a predictive marker of chemotherapy failure
(Generali et al., 2006). Thus, molecular targeting of
HIF-1a might help in the treatment of leptin-over-
expressing tumors.
Materials and methods
Cell culture and treatments
MCF-7 cells were grown as described before (Garofalo et al.,
2004). A total of 70% conﬂuent cultures were treated with
340 nM insulin (Sigma, St Louis, MO, USA), 100mM CoCl2
(Sigma) or a combination of both stimuli. Hypoxia was
accomplished by culturing the cells in a hypoxic chamber (Coy
Laboratories, Grass Lake, MI, USA) with 1% O2, 94% N2,
5% CO2 at 371C.
Western blotting
The cells were stimulated with 340 nM insulin and/or 100mM
CoCl2 for 4 h. The expression of proteins was analysed in 50–
100 mg of nuclear cell lysates obtained as described before
(Morelli et al., 2004). The following antibodies (Abs) were
used: HIF-1a mAb (B&D systems, Minneapolis, MN, USA),
b-tubulin H235 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and nucleolin mAb (Santa Cruz Biotechnology). The
intensity of bands was measured as described before (Morelli
et al., 2004).
Luciferase reporter assays
MCF-7 cells were grown in 24-well plates were transfected for
6 h with 0.5mg DNA mixture/well using Fugene 6 (Roche,
Indianapolis, IN, USA). The transfection mixtures contained
0.3 mg of the leptin promoter reporter plasmid pGL3-Ob1 (or
an empty vector pGL3) and 50 ng of a plasmid encoding
Renilla luciferase (RI Luc) (Promega, Madison, WI, USA).
The pGL3-Ob1 plasmid encodes the ﬁreﬂy luciferase (Luc)
cDNA under the leptin promoter (from 2924 to þ 31)
(Miller et al., 1996; De Vos et al., 1998). Upon transfection, the
cells were treated with 340 nM insulin and/or 100 mM CoCl2 for
4 h, or left untreated. Luciferase activity (Luc and RI Luc)
were measured as described before (Morelli et al., 2004).
Immunofluorescence/deconvoluted microscopy
A total of 5 104 MCF-7 cells were plated in 2-well Permanox
chamber slides (Nunc, Rockester, NY, USA). After 24 h, the
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cells were treated with 340 nM insulin and/or 100 mM CoCl2,
and/or hypoxia for 4 h (for HIF-1a detection) or 16 h (for
leptin detection). Then the cells were washed with PBS and
ﬁxed for 20min at 41C in 4% paraformaldehyde for HIF-1a
staining, or for 10min at 201C in methanol for leptin
staining. Next, the cells were permeabilized with 0.2% Triton
X-100, and unspeciﬁc binding was blocked in 7.5% BSA
fraction V for 1 h at room temperature. HIF-1a expression was
detected using 200 mg/ml HIF-1a pAb H-184 (Santa Cruz
Biotechnology) and rhodamine-conjugated donkey anti-rabbit
immunoglobulin G (IgG) (1:500, Santa Cruz Biotechnology).
Leptin expression was probed with 200mg/ml Ob pAb A-20
(Santa Cruz Biotechnology) and donkey anti-rabbit IgG-FITC
(1:500, Santa Cruz Biotechnology). In control experiments,
primary Abs were replaced by non-immune serum. The slides
were covered with Vectashield mounting medium containing
DAPI (Vector Laboratories, Burlingame, CA, USA) to allow
visualization of cell nuclei. The abundance of nuclear HIF-1a
and leptin was assessed using Olympus IX81 deconvoluted
microscope and Slidebook software. HIF-1a and leptin
expression were quantiﬁed by determining percentage of
positive cells in at least 10 viewing ﬁelds.
ELISA
A total of 1.3 107 MCF-7 cells were left untreated or were
treated for 16 h with 340 nM insulin, and/or 100 mM CoCl2
and/or cultured under hypoxic conditions with or without
insulin. Conditioned medium was collected and concentrated
with Amicon centrifugal ﬁlter 10K (Millipore, Billerica, CA,
USA) to ﬁnal volume of 500ml. Leptin abundance was
measured using the ELISA low range leptin kit (R&D
Systems, Minneapolis, MN, USA) following manufacturer’s
instructions.
Quantitative real-time–PCR
MCF-7 cells were treated for 4 h with 340 nM insulin, and/or
100 mM CoCl2 and/or hypoxia. Total RNA was isolated using
TRIzol (Invitrogen, Carlsbad, CA, USA). A total of 3 mg of
RNA was reverse transcribed using the TaqMan RT kit
(Applied Biosystems, Foster City, CA, USA). A total of 2 ml of
the RT products were used to amplify leptin sequences using
the Hs00174877 A1 Lep TaqMan kit (Applied Biosystems). To
normalize QRT–PCR reactions, parallel TaqMan assays were
run on each sample for a-actin. Leptin mRNA content relative
to a-actin mRNA was determined using a comparative CT
method (Applied Biosystems User Bulletin no. 2). An average
CT value for each RNA was obtained for replicate reactions.
Similar method was used to evaluate leptin mRNA levels in
HIF-1a siRNA-treated cells.
DNA affinity precipitation assay
Binding of nuclear HIF-1a to three HRE motifs (HRE-1:
region 103 to 134; HRE-2: 611 to 641 and HRE-3:
1511 to 1541) was assessed using DAPA protocol described
before (Cascio et al., 2007). Brieﬂy, 70mg of nuclear proteins
obtained from cells stimulated with 340 nM insulin and/or
100 mM CoCl2 for 4 h were mixed with 2 mg of speciﬁc
biotinylated DNA HRE probes in 400ml of Buffer D (Cascio
et al., 2007) and then precipitated with 50 ml of strepta-
vidin-agarose beads (Invitrogen). Upon removal of beads,
supernatants were analysed for the presence and abundance of
HIF-1a by western blot (WB).
The speciﬁc HRE probes were prepared by annealing a
biotinylated sense oligonucleotide (HRE-1, -2 and -3) with the
corresponding non-biotinylated antisense oligonucleotide. The
pairs were HRE-1: 50-Bio-CTAGCAGCCGCCCGGCACGT
CGCTACCCTGA-30 and 50-TCAGGGTAGCGACGTGCC
GGGCGGCTGCTAG-30; HRE-2: 50-Bio-TCCAGAGAGCG
TGCACTCCCTGGGGTGCCA-30 and 50-TGGCACCCCA
GGGAGTGCACGCTCTCTGGA; HRE-3: 50-Bio-TATCTG
GTGCCCAACGTGGGATACTGAGAT-30 and 50-ATCTC
AGTATCCCACGTTGGGCACCAGATA. The speciﬁcity of
probe–protein interactions was tested by addition of a 10-fold
excess of unlabeled probes.
Chromatin immunoprecipitation and reverse ChIP
MCF-7 cells were stimulated with 340 nM insulin and/or
100 mM CoCl2 for 4 h, or left untreated. Then, the cultures were
cross-linked with 1% formaldehyde and soluble chromatin was
obtained as described by us before (Morelli et al., 2004). To
precipitate HIF-1a associated chromatin, we used HIF-1a pAb
(Santa Cruz). A total of 5 ml sample of each HIF-1a ChIP
product was used to detect speciﬁc HREs by PCR. The
following primers were used: HRE-A (region from 992 to
þ 377) forward 50-GCGCAGTGGGGACCAGAA-30, reverse
50-CACCACCTCTGTGGAGTAG-30; HRE-B (1892 to
1403) forward 50-TTGTGGTCAGACCAGTTTTCT-30, re-
verse 50-GTTTGGTAATGCCCAAAAGCT-30. The PCR
conditions for HRE-A region were as follows: 1min at 941C,
1min at 531C, 1min 20 s at 721C. For HRE-B region: 1min
941C, 1min at 601C, 1min at 721C. The ampliﬁcation of HRE
regions was analysed after PCR 32 cycles. In control samples,
the primary Abs were replaced with non-immune rabbit IgG.
Re-ChIP (Morelli et al., 2004) was used to test the presence
of p300 associated with HIF-1a. HIF-1a ChIP pellets obtained
as described above were eluted, precipitated with p300 pAb
(Upstate Biotechnology/Millipore) and processed as for one-
step ChIP.
HIF1a RNA interference
HIF-1a expression was inhibited using the following siRNA
oligonucleotides: HIF siRNA I 50-UGAGGAAGUACCAUU
AUAUdTdT-30 and HIF siRNA II 50-UUAUGGUUCUCAC
AGAUGAdTdT-30 (Dharmacon, Lafayette, CO, USA). A
total of 800 nM of HIF-1a siRNA Iþ II was mixed with the
transfection agent RNAiFect (Qiagen, Valencia, CA, USA)
(siRNA:RNAiFect ratio 1:3) and incubated for 15min at room
temperature. Then the mixture was transfected into 70%
conﬂuent cultures of MCF-7 cells for 6 h. After that, the cells
were placed in fresh medium for 24 h and then treated with
340 nM insulin, and/or 100 mM CoCl2. As controls, we used
lamin A/C siRNA (Qiagen).
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